Ginkgo Cash And Equivalents from 2010 to 2024

DNA Stock  USD 8.26  0.31  3.90%   
Ginkgo Bioworks' Cash And Equivalents is increasing over the years with slightly volatile fluctuation. Cash And Equivalents is expected to dwindle to about 1 B. From 2010 to 2024 Ginkgo Bioworks Cash And Equivalents quarterly data regression line had arithmetic mean of  716,109,727 and r-squared of  0.47. View All Fundamentals
 
Cash And Equivalents  
First Reported
2010-12-31
Previous Quarter
1.5 B
Current Value
B
Quarterly Volatility
413 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Ginkgo Bioworks financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ginkgo Bioworks' main balance sheet or income statement drivers, such as Net Interest Income of 58 M, Interest Income of 60.1 M or Depreciation And Amortization of 75.1 M, as well as many indicators such as Price To Sales Ratio of 12.41, Dividend Yield of 0.0 or PTB Ratio of 2.85. Ginkgo financial statements analysis is a perfect complement when working with Ginkgo Bioworks Valuation or Volatility modules.
  
Check out the analysis of Ginkgo Bioworks Correlation against competitors.

Latest Ginkgo Bioworks' Cash And Equivalents Growth Pattern

Below is the plot of the Cash And Equivalents of Ginkgo Bioworks Holdings over the last few years. It is Ginkgo Bioworks' Cash And Equivalents historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ginkgo Bioworks' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 1.32 B10 Years Trend
Slightly volatile
   Cash And Equivalents   
       Timeline  

Ginkgo Cash And Equivalents Regression Statistics

Arithmetic Mean716,109,727
Geometric Mean633,976,318
Coefficient Of Variation57.68
Mean Deviation339,138,132
Median495,287,000
Standard Deviation413,025,359
Sample Variance170589.9T
Range1.2B
R-Value0.69
Mean Square Error96459.9T
R-Squared0.47
Significance0
Slope63,647,484
Total Sum of Squares2388259.3T

Ginkgo Cash And Equivalents History

2024B
20231.5 B
20221.3 B
20211.6 B
2020380.8 M

About Ginkgo Bioworks Financial Statements

Ginkgo Bioworks stakeholders use historical fundamental indicators, such as Ginkgo Bioworks' Cash And Equivalents, to determine how well the company is positioned to perform in the future. Although Ginkgo Bioworks investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ginkgo Bioworks' assets and liabilities are reflected in the revenues and expenses on Ginkgo Bioworks' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ginkgo Bioworks Holdings. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash And Equivalents1.5 BB

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ginkgo Bioworks Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ginkgo Bioworks' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ginkgo Bioworks Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ginkgo Bioworks Holdings Stock:
Check out the analysis of Ginkgo Bioworks Correlation against competitors.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. If investors know Ginkgo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ginkgo Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(12.89)
Revenue Per Share
4.291
Quarterly Revenue Growth
0.606
Return On Assets
(0.21)
Return On Equity
(0.64)
The market value of Ginkgo Bioworks Holdings is measured differently than its book value, which is the value of Ginkgo that is recorded on the company's balance sheet. Investors also form their own opinion of Ginkgo Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Ginkgo Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ginkgo Bioworks' market value can be influenced by many factors that don't directly affect Ginkgo Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ginkgo Bioworks' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ginkgo Bioworks is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ginkgo Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.